Dr. Hamlin on Future Combination Strategies in the MCL Landscape

Paul A. Hamlin, MD
Published: Wednesday, Sep 06, 2017



Paul A. Hamlin, MD, medical oncologist, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses future potential combination strategies in the mantle cell lymphoma (MCL) landscape.

This is likely where researchers are heading as a field, Hamlin explains. In MCL, the focus has really been in incorporating novel agents into treatment paradigms, as well as challenging whether or not autologous stem cell transplantation needs to be part of an induction regimen or whether or not the novel agents can give patients the same benefit in terms of disease control. Nevertheless, US and European investigators are looking at novel combinations, including a BCL-2 inhibitor plus a BCR inhibitor or PI3K inhibitor.

These are active areas of research, especially with incorporating these agents into a backbone of chemotherapy induction.


Paul A. Hamlin, MD, medical oncologist, chief, Basking Ridge Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses future potential combination strategies in the mantle cell lymphoma (MCL) landscape.

This is likely where researchers are heading as a field, Hamlin explains. In MCL, the focus has really been in incorporating novel agents into treatment paradigms, as well as challenging whether or not autologous stem cell transplantation needs to be part of an induction regimen or whether or not the novel agents can give patients the same benefit in terms of disease control. Nevertheless, US and European investigators are looking at novel combinations, including a BCL-2 inhibitor plus a BCR inhibitor or PI3K inhibitor.

These are active areas of research, especially with incorporating these agents into a backbone of chemotherapy induction.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x